AI assistant
Sending…
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2018
Sep 7, 2018
31580_dirs_2018-09-07_4fe84d8b-9117-46cf-b0f3-b9ba906f3be2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2018-09-05
Reporting Person: Alenson Carman (Principal Accounting Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-09-05 | Common stock | M | 312 | $52.29 | Acquired | 464 | Direct |
| 2018-09-05 | Common stock | S | 312 | $83.00 | Disposed | 152 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-09-05 | Stock option (right to buy) | $52.29 | M | 312 | Disposed | 2026-11-06 | Common stock (312) | Direct |
Footnotes
F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: Includes 152 shares purchased through the Company's employee stock purchase plan.
F3: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F4: This option was granted on November 7, 2016. The shares underlying this option vest as to 25% of the underlying shares on November 7, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.
More from AGIOS PHARMACEUTICALS, INC.
Interim / Quarterly Report
2026
Apr 29
Earnings Release
2026
Apr 29
Annual Report
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Major Shareholding Notification
2026
Mar 26
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3